Logo-jrip
Submitted: 10 Aug 2021
Accepted: 29 Aug 2021
ePublished: 04 Sep 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2022;11(4): e31947.
doi: 10.34172/jrip.2022.31947
  Abstract View: 173
  PDF Download: 60

Mini-Review

Ameliorative impact of sodium–glucose cotransporter-2 inhibitors in diabetic kidney disease; a mini- review to current evidence

Dorsa Jahangiri 1 ORCID logo, Atousa Najmaldin 2* ORCID logo, Lakkakula VKS Bhaskar 3 ORCID logo

1 Independent researcher, 43185 Cardston Place Leesburg Virginia, 20176, USA
2 Assistant Professor of Endocrinology & Metabolism, Department of Internal Medicine, School of Medicine, Semnan University of Medical Sciences
3 Professor of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India
*Corresponding Author: Corresponding author: Atousa Najmaldin, Email: najmaldinatousa@gmail.com, , Email: atousanajmodin@semums.ac.ir

Abstract

The sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a new class of antidiabetic agents. SGLT2i are able to inhibit SGLT2 transporter in renal tissue, increasing glycosuria and reducing blood sugar. These drugs act by inhibiting the SGLT2 in renal proximal epithelial tubular cells. SGLT2i are found to have beneficial effect on chronic renal failure caused by diabetic nephropathy.

Implication for health policy/practice/research/medical education:

A study of SGLT2 inhibitors in type 1 and 2 diabetes individuals showed a reduction in hyperfiltration in normotensive, normoalbuminuric type 1 diabetes patients and a significant reduction in albuminuria and hyperfiltration in type 2 diabetes individuals.

Please cite this paper as: Jahangiri D, Najmaldin A, Bhaskar LVKS. Ameliorative impact of sodium–glucose cotransporter-2 inhibitors in diabetic kidney disease; a mini- review to current evidence. J Renal Inj Prev. 2022; 11(4): e31947. doi: 10.34172/ jrip.2022.31947.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 174

Your browser does not support the canvas element.


PDF Download: 60

Your browser does not support the canvas element.